- Trial phase
- Phase 2 (not yet initiated)
- Time to market
- Several years away at minimum. The drug has not yet entered Phase 2 trials. Even if Phase 2 begins soon, the full clinical development path (Phase 2, Phase 3, regulatory filing) typically takes 4-7 years for a pain indication.
- Why 3/10
- No hard dated binary catalyst for PCRX-2002 exists in the next ~12 months; Phase 2 initiation (expected later in 2026) is a soft milestone, not a binary readout. More importantly, Pacira is being acquired by Viatris for $36.50/share via a tender offer expiring November 16, 2026, making the acquisition the sole relevant catalyst for the stock, not this individual pipeline asset.
The stock is trading at $36.39, essentially at Viatris's $36.50 tender offer price that expires November 16, 2026. The acquisition is the only relevant near-term catalyst for PCRX shares; PCRX-2002's Phase 2 initiation (expected later in 2026 per Q2 earnings) is a minor pipeline milestone at a company being acquired. Watch for any developments in the tender offer process or potential competing bids, though none have emerged since the October 8 announcement.
Price Chart
Executive Summary
PCRX-2002 is an early-stage (Phase 2, not yet enrolling) investigational hydrogel formulation of the non-opioid analgesic ropivacaine for postsurgical pain, in-licensed from AmacaThera in November 2025. It completed a Phase 1 PK study showing sustained release through 14 days. However, the drug is a minor pipeline asset at Pacira BioSciences, which is currently being acquired by Viatris (VTRS) for $36.50 per share in cash via a tender offer that commenced October 30, 2026. The stock trades at $36.39, essentially at the offer price, making the acquisition the dominant factor for shareholders rather than any individual pipeline catalyst.
How It Works
PCRX-2002 is a temperature-sensitive hydrogel (a gel-like substance) that is injected into the surgical site during an operation. It delivers ropivacaine, a numbing medication similar to what a dentist uses, in a controlled way: some is released immediately for rapid pain relief, while the rest releases slowly over more than 14 days to provide extended pain control from a single application. This is designed as a non-opioid alternative for managing pain after surgery.
Trial Status
A Phase 1 pharmacokinetic study in 30 healthy subjects showed ropivacaine release beginning immediately and continuing for more than 14 days. A Phase 2 study in bunionectomy surgery patients is planned but had not yet initiated as of the company's Q2 2026 earnings call in August 2026, when management said Phase 2 development was expected to begin later in 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 clinical trial initiation (expected later in 2026, per Q2 2026 earnings call)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Pacira BioSciences, Inc. SC 14D-9 PCRX ·Originating report